VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

General Updates | Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an overview of agents that are currently being evaluated in patients with myelofibrosis (MF) who have failed treatment with JAK inhibitors, including parsaclisib, pelabresib, navitoclax, imetelstat, and navtedmadlin. This interview took place virtually.

Disclosures

Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter